PROF Key Statistics, Chart & Performance
The current stock price of PROF is 8.44 USD. In the past month the price increased by 16.57%. In the past year, price increased by 11.49%.
PROF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About PROF
Company Profile
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Company Info
PROFOUND MEDICAL CORP
2400 Skymark Ave Unit 6
Mississauga ONTARIO L4W 5K5 CA
CEO: Arun Menawat
Employees: 131
Phone: 16474761350
PROFOUND MEDICAL CORP / PROF FAQ
What does PROF do?
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Can you provide the latest stock price for PROFOUND MEDICAL CORP?
The current stock price of PROF is 8.44 USD. The price decreased by -0.47% in the last trading session.
Does PROF stock pay dividends?
PROF does not pay a dividend.
What is the ChartMill rating of PROFOUND MEDICAL CORP stock?
PROF has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of PROFOUND MEDICAL CORP (PROF) based on its PE ratio?
PROFOUND MEDICAL CORP (PROF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).
Can you provide the number of employees for PROFOUND MEDICAL CORP?
PROFOUND MEDICAL CORP (PROF) currently has 131 employees.
What is PROFOUND MEDICAL CORP worth?
PROFOUND MEDICAL CORP (PROF) has a market capitalization of 254.80M USD. This makes PROF a Micro Cap stock.
PROF Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PROF. When comparing the yearly performance of all stocks, PROF is one of the better performing stocks in the market, outperforming 85.34% of all stocks.
PROF Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PROF. While PROF has a great health rating, there are worries on its profitability.
PROF Financial Highlights
Over the last trailing twelve months PROF reported a non-GAAP Earnings per Share(EPS) of -1.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93% | ||
| ROE | -122.4% | ||
| Debt/Equity | 0 |
PROF Forecast & Estimates
6 analysts have analysed PROF and the average price target is 11.35 USD. This implies a price increase of 34.44% is expected in the next year compared to the current price of 8.44.
For the next year, analysts expect an EPS growth of -32.56% and a revenue growth 55.62% for PROF